Taiwan Bio Therapeutics Co., Ltd. (6892) Stock Statistics & Valuation Metrics
Total Valuation
Taiwan Bio Therapeutics Co., Ltd. has a market cap or net worth of TWD 2.29B. The enterprise value is ―.
- Market Cap
- TWD 2.29B
- Enterprise Value
- ―
Share Statistics
Taiwan Bio Therapeutics Co., Ltd. has 94,015,230 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 94,015,230
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Taiwan Bio Therapeutics Co., Ltd.’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -29.68%.
- Return on Equity (ROE)
- -0.52
- Return on Assets (ROA)
- -0.28
- Return on Invested Capital (ROIC)
- -29.68%
- Return on Capital Employed (ROCE)
- -0.31
- Revenue Per Employee
- 2.52M
- Profits Per Employee
- -19.08M
- Employee Count
- 20
- Asset Turnover
- 0.04
- Inventory Turnover
- 0.59
Valuation Ratios
The current PE Ratio of Taiwan Bio Therapeutics Co., Ltd. is -5.81. Taiwan Bio Therapeutics Co., Ltd.’s PEG ratio is 0.16.
- PE Ratio
- -5.81
- PS Ratio
- 48.85
- PB Ratio
- 3.04
- Price to FCF
- -10.08
- Price to Operating Cash Flow
- -10.44
- PEG Ratio
- 0.16
Income Statement
In the last 12 months, Taiwan Bio Therapeutics Co., Ltd. had revenue of 50.43M and earned -381.65M in profits. Earnings per share was -4.51.
- Revenue
- 50.43M
- Gross Profit
- 32.14M
- Operating Income
- -385.33M
- Pretax Income
- -381.60M
- Net Income
- -381.65M
- EBITDA
- -259.98M
- Earnings Per Share (EPS)
- -4.51
Cash Flow
In the last 12 months, operating cash flow was -265.12M and capital expenditures -35.28M, giving a free cash flow of -300.40M billion.
- Operating Cash Flow
- -265.12M
- Free Cash Flow
- -300.40M
- Free Cash Flow per Share
- -2.89
Dividends & Yields
Taiwan Bio Therapeutics Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -10.10%
- Earnings Yield
- -17.51%
Stock Price Statistics
- Beta
- 0.26
- 52-Week Price Change
- -19.47%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 35.77
- Average Volume (3m)
- 138.30K
Financial Position
Taiwan Bio Therapeutics Co., Ltd. as a current ratio of 4.01, with Debt / Equity ratio of 43.68%
- Current Ratio
- 4.01
- Quick Ratio
- 3.67
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.11
- Interest Coverage Ratio
- -54.38
Taxes
In the past 12 months, Taiwan Bio Therapeutics Co., Ltd. has paid 50.00K in taxes.
- Income Tax
- 50.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Taiwan Bio Therapeutics Co., Ltd. EV to EBITDA ratio is -9.42, with an EV/FCF ratio of -10.02.
- EV to Sales
- 48.57
- EV to EBITDA
- -9.42
- EV to Free Cash Flow
- -10.02
- EV to Operating Cash Flow
- -11.54
Balance Sheet
Taiwan Bio Therapeutics Co., Ltd. has TWD 529.60M in cash and marketable securities with TWD 329.48M in debt, giving a net cash position of TWD 200.12M billion.
- Cash & Marketable Securities
- TWD 529.60M
- Total Debt
- TWD 329.48M
- Net Cash
- TWD 200.12M
- Net Cash Per Share
- TWD 2.13
- Tangible Book Value Per Share
- TWD 10.52
Margins
Gross margin is 63.74%, with operating margin of -764.16%, and net profit margin of -756.85%.
- Gross Margin
- 63.74%
- Operating Margin
- -764.16%
- Pretax Margin
- -756.75%
- Net Profit Margin
- -756.85%
- EBITDA Margin
- -515.57%
- EBIT Margin
- -764.16%
